Find Omaveloxolone manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0
API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1474034-05-3, Rta-408, Rta 408, Nrf1-activator-1, Omaveloxolone [inn], Rta408
Molecular Formula
C33H44F2N2O3
Molecular Weight
554.7  g/mol
InChI Key
RJCWBNBKOKFWNY-IDPLTSGASA-N
FDA UNII
G69Z98951Q

Omaveloxolone
Omaveloxolone is a member of the synthetic oleanane triterpenoid class of compounds and an activator of nuclear factor erythroid 2 [NF-E2]-related factor 2 (Nrf2, Nfe2l2), with potential chemopreventive activity. Upon administration, omaveloxolone activates the cytoprotective transcription factor Nrf2. In turn, Nrf2 translocates to the nucleus, dimerizes with a small Maf protein (sMaf), and binds to the antioxidant response element (ARE). This induces the expression of a number of cytoprotective genes, including NAD(P)H quinone oxidoreductase 1 (NQO1), sulfiredoxin 1 (Srxn1), heme oxygenase-1 (HO1, HMOX1), superoxide dismutase 1 (SOD1), gamma-glutamylcysteine synthetase (gamma-GCS), thioredoxin reductase-1 (TXNRD1), glutathione S-transferase (GST), glutamate-cysteine ligase catalytic subunit (Gclc) and glutamate-cysteine ligase regulatory subunit (Gclm), and increases the synthesis of the antioxidant glutathione (GSH). Nrf2, a leucine zipper transcription factor, plays a key role in the maintenance of redox balance and cytoprotection against oxidative stress.
1 2D Structure

Omaveloxolone

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
2.1.2 InChI
InChI=1S/C33H44F2N2O3/c1-27(2)11-13-33(37-26(40)32(8,34)35)14-12-31(7)24(20(33)17-27)21(38)15-23-29(5)16-19(18-36)25(39)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3,(H,37,40)/t20-,22-,24-,29-,30+,31+,33-/m0/s1
2.1.3 InChI Key
RJCWBNBKOKFWNY-IDPLTSGASA-N
2.1.4 Canonical SMILES
CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)NC(=O)C(C)(F)F)C
2.1.5 Isomeric SMILES
C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)NC(=O)C(C)(F)F
2.2 Other Identifiers
2.2.1 UNII
G69Z98951Q
2.3 Synonyms
2.3.1 MeSH Synonyms

1. N-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2h-picen-4a-yl)-2-2-difluoropropionamide

2. Rta 408

3. Rta-408

2.3.2 Depositor-Supplied Synonyms

1. 1474034-05-3

2. Rta-408

3. Rta 408

4. Nrf1-activator-1

5. Omaveloxolone [inn]

6. Rta408

7. G69z98951q

8. N-[(4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide

9. Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-

10. N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide

11. Unii-g69z98951q

12. Omaveloxolone (usan/inn)

13. Omaveloxolone [usan]

14. Omaveloxolone [who-dd]

15. Gtpl7573

16. Chembl4303525

17. Schembl15349371

18. Ex-a541

19. Dtxsid101138251

20. Bcp28609

21. Mfcd28167769

22. Akos037648676

23. Zinc144682962

24. Db12513

25. Bs-15146

26. Hy-12212

27. N-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2h-picen-4a-yl)-2-2-difluoropropionamide

28. D10964

29. Rta408; Rta408; Rta-408;nrf1-activator-1

30. Q21098900

31. N-((4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide

2.4 Create Date
2013-11-18
3 Chemical and Physical Properties
Molecular Weight 554.7 g/mol
Molecular Formula C33H44F2N2O3
XLogP36.7
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count6
Rotatable Bond Count2
Exact Mass554.33199959 g/mol
Monoisotopic Mass554.33199959 g/mol
Topological Polar Surface Area87 Ų
Heavy Atom Count40
Formal Charge0
Complexity1320
Isotope Atom Count0
Defined Atom Stereocenter Count7
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

API SUPPLIERS

read-more
read-more

01

American Pacific Corporation

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

The MedTech Conference
Not Confirmed
arrow

American Pacific Corporation

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
The MedTech Conference
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

02

Hovione

Portugal

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

The MedTech Conference
Not Confirmed
arrow

Hovione

Portugal

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
The MedTech Conference
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

Pharma MES 2025
Not Confirmed
arrow
arrow
Pharma MES 2025
Not Confirmed

OMAVELOXOLONE

NDC Package Code : 50683-0525

Start Marketing Date : 2023-02-28

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

Hovione LLC

Portugal
Pharma MES 2025
Not Confirmed
arrow

Hovione LLC

Portugal
arrow
Pharma MES 2025
Not Confirmed

OMAVELOXOLONE

NDC Package Code : 42052-1702

Start Marketing Date : 2024-07-05

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.


Lead Product(s): Omaveloxolone,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 13, 2025

blank

01

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Details : Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 13, 2025

blank

Details:

Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Friedreich Ataxia.


Lead Product(s): Omaveloxolone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 01, 2025

blank

02

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Details : Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Friedreich Ataxia.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 01, 2025

blank

Details:

Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Omaveloxolone,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 25, 2024

blank

03

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Details : Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 25, 2024

blank

Details:

Skyclarys (omaveloxolone) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with Friedreich’s ataxia.


Lead Product(s): Omaveloxolone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Skyclarys

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 12, 2024

blank

04

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Details : Skyclarys (omaveloxolone) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with Friedreich’s ataxia.

Product Name : Skyclarys

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 12, 2024

blank

Details:

Skyclarys (omaveloxolone) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with Friedreich’s ataxia.


Lead Product(s): Omaveloxolone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Skyclarys

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 15, 2023

blank

05

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Details : Skyclarys (omaveloxolone) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with Friedreich’s ataxia.

Product Name : Skyclarys

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 15, 2023

blank

Details:

Skyclarys (omaveloxolone) is an oral, once-daily medication indicated for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older.


Lead Product(s): Omaveloxolone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Skyclarys

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 15, 2023

blank

06

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Details : Skyclarys (omaveloxolone) is an oral, once-daily medication indicated for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older.

Product Name : Skyclarys

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 15, 2023

blank

Details:

Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Friedreich Ataxia.


Lead Product(s): Omaveloxolone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 26, 2023

blank

07

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Details : Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Friedreich Ataxia.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 26, 2023

blank

Details:

Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.


Lead Product(s): Omaveloxolone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Biogen

Deal Size: $7,300.0 million Upfront Cash: $7,300.0 million

Deal Type: Acquisition September 26, 2023

blank

08

Pharma MES 2025
Not Confirmed
Pharma MES 2025
Not Confirmed

Details : Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : $7,300.0 million

September 26, 2023

blank

Details:

Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.


Lead Product(s): Omaveloxolone,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Biogen

Deal Size: $7,300.0 million Upfront Cash: $7,300.0 million

Deal Type: Acquisition July 28, 2023

blank

09

Pharma MES 2025
Not Confirmed
Pharma MES 2025
Not Confirmed

Details : Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : $7,300.0 million

July 28, 2023

blank

Details:

Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Omaveloxolone,Moxifloxacin

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Celerion | Q2 Solutions

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 03, 2023

blank

10

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Biogen

U.S.A
arrow
Pharma MES 2025
Not Confirmed

Details : Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 03, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1474034-05-3 / Omaveloxolone API manufacturers, exporters & distributors?

Omaveloxolone manufacturers, exporters & distributors 1

92

PharmaCompass offers a list of Omaveloxolone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Omaveloxolone manufacturer or Omaveloxolone supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Omaveloxolone manufacturer or Omaveloxolone supplier.

PharmaCompass also assists you with knowing the Omaveloxolone API Price utilized in the formulation of products. Omaveloxolone API Price is not always fixed or binding as the Omaveloxolone Price is obtained through a variety of data sources. The Omaveloxolone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Omaveloxolone

Synonyms

1474034-05-3, Rta-408, Rta 408, Nrf1-activator-1, Omaveloxolone [inn], Rta408

Cas Number

1474034-05-3

Unique Ingredient Identifier (UNII)

G69Z98951Q

About Omaveloxolone

Omaveloxolone is a member of the synthetic oleanane triterpenoid class of compounds and an activator of nuclear factor erythroid 2 [NF-E2]-related factor 2 (Nrf2, Nfe2l2), with potential chemopreventive activity. Upon administration, omaveloxolone activates the cytoprotective transcription factor Nrf2. In turn, Nrf2 translocates to the nucleus, dimerizes with a small Maf protein (sMaf), and binds to the antioxidant response element (ARE). This induces the expression of a number of cytoprotective genes, including NAD(P)H quinone oxidoreductase 1 (NQO1), sulfiredoxin 1 (Srxn1), heme oxygenase-1 (HO1, HMOX1), superoxide dismutase 1 (SOD1), gamma-glutamylcysteine synthetase (gamma-GCS), thioredoxin reductase-1 (TXNRD1), glutathione S-transferase (GST), glutamate-cysteine ligase catalytic subunit (Gclc) and glutamate-cysteine ligase regulatory subunit (Gclm), and increases the synthesis of the antioxidant glutathione (GSH). Nrf2, a leucine zipper transcription factor, plays a key role in the maintenance of redox balance and cytoprotection against oxidative stress.

Omaveloxolone Manufacturers

A Omaveloxolone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Omaveloxolone, including repackagers and relabelers. The FDA regulates Omaveloxolone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Omaveloxolone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Omaveloxolone Suppliers

A Omaveloxolone supplier is an individual or a company that provides Omaveloxolone active pharmaceutical ingredient (API) or Omaveloxolone finished formulations upon request. The Omaveloxolone suppliers may include Omaveloxolone API manufacturers, exporters, distributors and traders.

click here to find a list of Omaveloxolone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Omaveloxolone NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Omaveloxolone as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Omaveloxolone API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Omaveloxolone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Omaveloxolone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Omaveloxolone NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Omaveloxolone suppliers with NDC on PharmaCompass.

Omaveloxolone GMP

Omaveloxolone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Omaveloxolone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Omaveloxolone GMP manufacturer or Omaveloxolone GMP API supplier for your needs.

Omaveloxolone CoA

A Omaveloxolone CoA (Certificate of Analysis) is a formal document that attests to Omaveloxolone's compliance with Omaveloxolone specifications and serves as a tool for batch-level quality control.

Omaveloxolone CoA mostly includes findings from lab analyses of a specific batch. For each Omaveloxolone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Omaveloxolone may be tested according to a variety of international standards, such as European Pharmacopoeia (Omaveloxolone EP), Omaveloxolone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Omaveloxolone USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty